Genital HPV enfeksiyonu ve koruyucu HPV aşıları Çağrılı Editör

Human Papillomavirus HPV enfeksiyonunun bazı yardımcı etmenlerin de etkisiyle serviks kanserine yol açtığı günümüzde kabul görmektedir Bunun yanısıra genital enfeksiyonlar arasında da HPV’nin rolü giderek artmaktadır Koruyucu HPV aşıları serviks salgısında nötralizan antikor miktarını artırarak virüsün buradan içeri girmesini immünolojik olarak önlemektedir Bu aşılar ile servikal preinvazif lezyonlar ve servikal kanser gelişimini önlemek amaçlanmaktadır Bu konu ile ilgili çalışmaların ortak sonuçları HPV VLP aşılarının iyi tolere edildiği ve yüksek oranda immünojenik olduğu yüksek antikor seviyelerine sebep oldukları dirençli HPV enfeksiyonu ve HPV ilişkili klinik hastalığın azaltılmasında etkili oldukları yönündedir Servikal kanserden korunmada aşılamanın en azından bugünkü uygulamalardan daha başarılı olacağı öngörülmektedir Türk Ped Arş 2008; 43: 1 8 Anahtar kelimeler: Enfeksiyon HPV serviks kanseri

Anahtar Kelimeler:

Enfeksiyon, HPV, serviks kanseri

Genital HPV infection and prophylactic HPV vaccines Invited Editor

Human Papillomavirus HPV infection is accepted as the cause of cervical cancer Besides HPV infection is a growing health problem Prophylactic HPV vaccines immunologically block the virus by increasing the neutralizing antibodies in cervical secretions These vaccines aim to stop the development of cervical preinvasive lesions and cervical cancer The prospective studies proved that these vaccines were well tolerated; highly immunogenic resulting in high antibody titers decreasing persistent HPV infections and HPV related cervical disease It can be postulated that vaccination against HPV will be superior to current protection strategies Turk Arch Ped 2008; 43: 1 8 Key words: Cervical cancer HPV infection

Keywords:

-,

PDF

___

Pagliusi, S. World Health Organization. Human papillomavirus infection and cervical cancer. Available at: http://www.who.int/vaccine_research/ diseases/hpv/en/ 2006.
American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine use to prevent cervical cancer and its precur- sors, CA. Cancer J Clin 2007;57:7–28.
Walboomers JM, Jacobs MV, Manos MM, et al. Human papil- lomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-9.
Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Rela
tion of human papillomavirus status to cervical lesions and con- sequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20-5.
Bosch FX, Munoz N. The viral etiology of cervical cancer.Virus Res 2002;89:183-90.
Koutsky L. Epidemiology of genital human papillomavirus in- fection. Am J Med 1997;102:3-8.
Centers for Disease Control and Prevention (CDC). Update: changes in notifiable disease surveillance data-United States, 1992-1993. MMWR Morb Mortal Wkly Rep1993 29;42:824-36.
Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young wo- men. N Engl J Med 1998; 338:423-8.
Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001;183:1554–64.
Ley C, Bauer HM, Reingold A, et al. Determinants of genital hu- man papillomavirus infection in young women. J Natl Cancer Inst 1991; 83:997-1003.
Sellors JW, Karwalajtys TL, Kaczorowski J, et al. Incidence, cle- arance and predictors of human papillomavirus infection in wo- men. Can Med Assoc J 2003; 168:421-5.
Coppleson M, Reid B. The etiology of squamous carcinoma of the cervix. Obstet Gynecol 1968; 32:432-6.
Munoz N, Castellsague X, Gonzales AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24: 1-10.
Burd EM. Human papillomavirus and cervical cancer. Clin Mic- robiol Rev 2003;16:1-17.
Burchell AN, Winer RL, Sajose S, Franco EL. Chapter 6: Epide- miology and tranmission dynamics of genital HPV infection. Vaccine 2006;24:52-61.
Stanley M. Immune responses to human papillomavirus. Vacci- ne 2006;24:S16-22.
Munger K. The role of human papillomaviruses in human can- cers. Front Biosci 2002;7:d641-9.
Ferenczy A, Mitao M, Nagai N, Silverstein SJ, Crum CP. Latent papillomavirus and recurring genital warts. N Engl J Med 1985; 313:784-8.
Galloway DA, McDougall JK. The disruption of cell cycle check- points by papillomavirus oncoproteins contributes to anogeni- tal neoplasia. Semin Cancer Biol 1996;7:309-15.
Matsukura T, Koi S, Sugase M. Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology 1989;172:63-72.
Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of hu- man papillomavirus infection in HIV-infected and-uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004;190:37-45.
Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dill- ner J. Clinical utility of HPV-DNA detection: triage of minor cer- vical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 2005;99:S7-11.
Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12:186-92.
Nasiell K, Roger V, Nasiell M. Behavior of mild cervical dysplasi- a during long-term follow-up. Obstet Gynecol 1986;67:665-9.
Melnikow J, Nuovo J, Willan AR, et al. Natural history of cervi- cal squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;92:727-35.
Cuzick J, Terry G, Ho L, et al. Type-specific human papilloma- virus DNA in abnormal smears as a predictor of high-grade cer- vical intraepithelial neo-plasia. Br J Cancer 1994;69:167-71.
Castle PE, Solomon D, Schiffman M, Wheeler CM. Human pa- pillomavirus type 16 infections and 2-year absolute risk of cer- vical precancer in women with equivocal or mild cytologic ab- normalities. J Natl Cancer Inst 2005;97:1066-71.
Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papil- lomavirus (HPV) type 16 or 18 and the possible utility of type- specific HPV testing in clinical practice. J Natl Cancer Inst. 2005 20;97:1072-9.
Sillman FH, Sentovich S, Shaffer D. Ano-genital neoplasia in re- nal transplant patients. Ann Transplant 1997;2:59-66.
Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005;337:76-84.
Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69:3959-63.
Jansen KU, Rosolowsky M, Schultz LD, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus- like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995;13:1509-14.
Koutsky LA, Ault KA, Wheeler CM, et al. Proof of Principle Study Investigators. A controlled trial of a human papillomavi- rus type 16 vaccine. N Engl J Med 2002;347:1645-51.
Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
Garland SM, Hernandez-Avila M, Wheeler CM, et al. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with hu- man papillomavirus types 16 and 18 in young women: a rando- mised controlled trial. Lancet 2004;364:1757-65.
Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine aga- inst human papillo-mavirus types 16 and 18: follow-up from a ran-domised control trial. Lancet 2006; 367:1247–55.
Sanders GD, Taira AV. Cost-effectiveness of a potential vacci- ne for human papillomavirus. Emerg Infect Dis 2003;9:37-48.
Franco EL, Harper DM. Vaccination against human papillomavi- rus infection: a new paradigm in cervical cancer control. Vacci- ne 2005 18;23:2388-94.
Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Ham-mouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international pers- pective. Int J Cancer 2004;111:278–85.
Kulasingam SL,Myers ER. Potential health and economic im- pact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-9.
Bozon M. Sexuality, gender, and the couple: a sociohistorical perspective. Annu Rev Sex Res 2001;12:1-32.
Schwarz TF. An ASO4 containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well tolerated in women 15-55 years old. J Clin Oncol 2006;24:1008.
American College of Obstetricians and Gynecologists Comitee Opinion 344: September 2006. Obstet Gynecol 2006; 108:699- 705.
Parkin DM, Bray F. Chapter 2: The burden of HPV-related can- cers. Vaccine 2006;24 Suppl 3:S11-25.
Anhang R, Wright TC Jr, Smock L, Goldie SJ. Women's desi- red information about human papillomavirus. Cancer 2004;100:315-20.
Monsenego J. Prevention of cervical cancer: Challenges and perspectives of HPV prophylactic vaccines. In: Monsenego J (ed). Emerging issues in HPV infections. From Science to Prac- tice. Basel: Karger, 2006:184-205.
Sherman ME, Schiffman MH, Strickler H, Hildesheim A. Prospects for a prophylactic HPV vaccine: rationale and future implications for cervical cancer screening. Diagn Cytopathol 1998; 18:5-9.